Isoproterenol
As of the edition of 20 October 2026, Isoproterenol is a small molecule: marketed, first approved in 1969 (ES); acts on ADRB1, ADRB2 and ADRB3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2020
- Kind
- Small molecule
- Brand name
- Isuprel
- First approved
- 1 January 1969 (ES)
- Approvals on record
- 18 in 3 regions
- Holder of the most recent approval
- MARCAN PHARMACEUTICALS INC; 10 holders in all
- Registered trials
- 17, 0 stopped early
- Disease areas
- Heart and blood vessels; Nervous system; Cancer; Mental health; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route B and 2 company-target rows on route A because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Isoproterenol.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Companies on route A for this drug
In the product2 company-target rows are on route A because of Isoproterenol.
See the 2 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 8 | 5 | 2 | 0 |
| Phase 1 | 4 | 1 | 3 | 0 |
| Phase 2 | 3 | 2 | 0 | 0 |
| Phase 4 | 2 | 0 | 2 | 0 |
| All trials | 17 |